Skip to main navigation Skip to search Skip to main content

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active in Rheumatoid Arthritis (ReAct) trial.

Translated title of the contribution: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active in Rheumatoid Arthritis (ReAct) trial.
  • G.R. Burmester
  • , X. Mariette
  • , C. Montecucco
  • , I. Monteagudo-Saez
  • , M. Malaise
  • , A.G. Tzioufas
  • , J.W.J. Bijlsma
  • , K. Unnebrink
  • , S. Kary
  • , H. Kupper

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active in Rheumatoid Arthritis (ReAct) trial.
Original languageUndefined/Unknown
Pages (from-to)732-739
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume66
Issue number6
Publication statusPublished - 2007

Cite this